April 30, 2021
The Japan arm of Amgen said on April 28 that it has filed a new drug application in the country for its KRAS G12C inhibitor sotorasib (AMG510) for the treatment of KRAS G12C-mutated unresectable, advanced/relapsed non-small cell lung cancer (NSCLC)...read more